Survival analysis of high-intensity focused ultrasound therapy vs. transarterial chemoembolization for unresectable hepatocellular carcinomas
Background & Aims High‐intensity focused ultrasound (HIFU) ablation is a non‐invasive treatment for unresectable hepatocellular carcinomas (HCCs), but long‐term survival analysis is lacking. This study was to analyse its outcome compared to that of transarterial chemoembolization (TACE). Methods...
Gespeichert in:
| Veröffentlicht in: | Liver international 2014-07, Vol.34 (6), p.e136-e143 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e143 |
|---|---|
| container_issue | 6 |
| container_start_page | e136 |
| container_title | Liver international |
| container_volume | 34 |
| creator | Cheung, Tan To Poon, Ronnie T. P. Jenkins, Caroline R. Chu, Ferdinand S. K. Chok, Kenneth S. H. Chan, Albert C. Y. Tsang, Simon H. Y. Dai, Wing Chiu Yau, Thomas C. C. Chan, See Ching Fan, Sheung Tat Lo, Chung Mau |
| description | Background & Aims
High‐intensity focused ultrasound (HIFU) ablation is a non‐invasive treatment for unresectable hepatocellular carcinomas (HCCs), but long‐term survival analysis is lacking. This study was to analyse its outcome compared to that of transarterial chemoembolization (TACE).
Methods
From October 2003 to September 2010, 113 patients received HIFU ablation as a treatment of HCCs at our hospital. Twenty‐six patients had HCCs sized 3–8 cm. Fifty‐two patients with matched tumour characteristics having TACE as primary treatment were selected for comparison. Short‐term outcome and long‐term survival were analysed.
Results
In the HIFU group (n = 26), 46 tumours were ablated. The median age of the patients was 69 (49–84) years. The median tumour size was 4.2 (3–8) cm. In the TACE group (n = 52), the median age of the patients was 67 (44–84) years. The median tumour size was 4.8 (3–8) cm. There was no hospital mortality in any of the groups. In the HIFU group, the rates of complete tumour response, partial tumour response, stable disease and progressive disease were 50%, 7.7%, 25.6% and 7.7% respectively, according to the modified Response Evaluation Criteria in Solid Tumours. The TACE group had the corresponding rates at 0%, 21.2%, 63.5% and 15.4% respectively (P |
| doi_str_mv | 10.1111/liv.12474 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1668249911</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1537184918</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4624-80d79007ccb653b579107e55a3cb66e86b57efd0f9101fffbaaf2f87c79d23833</originalsourceid><addsrcrecordid>eNqFkcFu1DAURSMEoqWw4AeQl7DI1I6dOFlCgaHSCBZAkdhYL84zY3DiwXYGwj_wz7hMOzuEN7auzj2ydIviMaMrls-5s_sVq4QUd4pTJmRb8oqzu8d3xU-KBzF-pZR1Xc3uFyeVEDWjVXNa_H4_h73dgyMwgVuijcQbsrVftqWdEk7RpoUYr-eIA5ldChD9PA0kbTHAbiH7uCI5nCKEhMFmj97i6HHsvbO_IFk_5Xog8xQwok7QOyRb3EHyGp2bHQSiIWg7-RHiw-KeARfx0c19Vnx8_erDxZty8259efF8U2rRVKJs6SA7SqXWfVPzvpYdoxLrGngOGmybHKEZqMk5M8b0AKYyrdSyGyrecn5WPD14d8F_nzEmNdp4_R-Y0M9RsaZpK9F1jP0frblkrehYm9FnB1QHH2NAo3bBjhAWxai6HkrlodTfoTL75EY79yMOR_J2mQycH4Af1uHyb5PaXF7dKstDw8aEP48NCN9UI7ms1ae3a7UWmxfN1eeXquN_AEBDsFc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1537184918</pqid></control><display><type>article</type><title>Survival analysis of high-intensity focused ultrasound therapy vs. transarterial chemoembolization for unresectable hepatocellular carcinomas</title><source>Access via Wiley Online Library</source><source>MEDLINE</source><creator>Cheung, Tan To ; Poon, Ronnie T. P. ; Jenkins, Caroline R. ; Chu, Ferdinand S. K. ; Chok, Kenneth S. H. ; Chan, Albert C. Y. ; Tsang, Simon H. Y. ; Dai, Wing Chiu ; Yau, Thomas C. C. ; Chan, See Ching ; Fan, Sheung Tat ; Lo, Chung Mau</creator><creatorcontrib>Cheung, Tan To ; Poon, Ronnie T. P. ; Jenkins, Caroline R. ; Chu, Ferdinand S. K. ; Chok, Kenneth S. H. ; Chan, Albert C. Y. ; Tsang, Simon H. Y. ; Dai, Wing Chiu ; Yau, Thomas C. C. ; Chan, See Ching ; Fan, Sheung Tat ; Lo, Chung Mau</creatorcontrib><description>Background & Aims
High‐intensity focused ultrasound (HIFU) ablation is a non‐invasive treatment for unresectable hepatocellular carcinomas (HCCs), but long‐term survival analysis is lacking. This study was to analyse its outcome compared to that of transarterial chemoembolization (TACE).
Methods
From October 2003 to September 2010, 113 patients received HIFU ablation as a treatment of HCCs at our hospital. Twenty‐six patients had HCCs sized 3–8 cm. Fifty‐two patients with matched tumour characteristics having TACE as primary treatment were selected for comparison. Short‐term outcome and long‐term survival were analysed.
Results
In the HIFU group (n = 26), 46 tumours were ablated. The median age of the patients was 69 (49–84) years. The median tumour size was 4.2 (3–8) cm. In the TACE group (n = 52), the median age of the patients was 67 (44–84) years. The median tumour size was 4.8 (3–8) cm. There was no hospital mortality in any of the groups. In the HIFU group, the rates of complete tumour response, partial tumour response, stable disease and progressive disease were 50%, 7.7%, 25.6% and 7.7% respectively, according to the modified Response Evaluation Criteria in Solid Tumours. The TACE group had the corresponding rates at 0%, 21.2%, 63.5% and 15.4% respectively (P < 0.0001). The 1‐year, 3‐year and 5‐year survival rates were 84.6%, 49.2% and 32.3% respectively, in the HIFU group and 69.2%, 29.8% and 2.3% respectively, in the TACE group (P = 0.001).
Conclusion
HIFU ablation is a safe and effective method for unresectable HCCs. A survival benefit is observed over sole TACE.</description><identifier>ISSN: 1478-3223</identifier><identifier>EISSN: 1478-3231</identifier><identifier>DOI: 10.1111/liv.12474</identifier><identifier>PMID: 24451026</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Aged ; Aged, 80 and over ; Carcinoma, Hepatocellular - blood supply ; Carcinoma, Hepatocellular - mortality ; Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - therapy ; Chemoembolization, Therapeutic - adverse effects ; Chemoembolization, Therapeutic - mortality ; Disease Progression ; Female ; HCC ; HIFU ; High-Intensity Focused Ultrasound Ablation - adverse effects ; High-Intensity Focused Ultrasound Ablation - mortality ; Hong Kong ; Humans ; Kaplan-Meier Estimate ; liver cancer ; Liver Neoplasms - blood supply ; Liver Neoplasms - mortality ; Liver Neoplasms - pathology ; Liver Neoplasms - therapy ; Male ; Middle Aged ; morbidity ; mortality ; non-invasive treatment ; Risk Factors ; survival ; Time Factors ; Treatment Outcome ; Tumor Burden</subject><ispartof>Liver international, 2014-07, Vol.34 (6), p.e136-e143</ispartof><rights>2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4624-80d79007ccb653b579107e55a3cb66e86b57efd0f9101fffbaaf2f87c79d23833</citedby><cites>FETCH-LOGICAL-c4624-80d79007ccb653b579107e55a3cb66e86b57efd0f9101fffbaaf2f87c79d23833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fliv.12474$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fliv.12474$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,27933,27934,45583,45584</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24451026$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cheung, Tan To</creatorcontrib><creatorcontrib>Poon, Ronnie T. P.</creatorcontrib><creatorcontrib>Jenkins, Caroline R.</creatorcontrib><creatorcontrib>Chu, Ferdinand S. K.</creatorcontrib><creatorcontrib>Chok, Kenneth S. H.</creatorcontrib><creatorcontrib>Chan, Albert C. Y.</creatorcontrib><creatorcontrib>Tsang, Simon H. Y.</creatorcontrib><creatorcontrib>Dai, Wing Chiu</creatorcontrib><creatorcontrib>Yau, Thomas C. C.</creatorcontrib><creatorcontrib>Chan, See Ching</creatorcontrib><creatorcontrib>Fan, Sheung Tat</creatorcontrib><creatorcontrib>Lo, Chung Mau</creatorcontrib><title>Survival analysis of high-intensity focused ultrasound therapy vs. transarterial chemoembolization for unresectable hepatocellular carcinomas</title><title>Liver international</title><addtitle>Liver Int</addtitle><description>Background & Aims
High‐intensity focused ultrasound (HIFU) ablation is a non‐invasive treatment for unresectable hepatocellular carcinomas (HCCs), but long‐term survival analysis is lacking. This study was to analyse its outcome compared to that of transarterial chemoembolization (TACE).
Methods
From October 2003 to September 2010, 113 patients received HIFU ablation as a treatment of HCCs at our hospital. Twenty‐six patients had HCCs sized 3–8 cm. Fifty‐two patients with matched tumour characteristics having TACE as primary treatment were selected for comparison. Short‐term outcome and long‐term survival were analysed.
Results
In the HIFU group (n = 26), 46 tumours were ablated. The median age of the patients was 69 (49–84) years. The median tumour size was 4.2 (3–8) cm. In the TACE group (n = 52), the median age of the patients was 67 (44–84) years. The median tumour size was 4.8 (3–8) cm. There was no hospital mortality in any of the groups. In the HIFU group, the rates of complete tumour response, partial tumour response, stable disease and progressive disease were 50%, 7.7%, 25.6% and 7.7% respectively, according to the modified Response Evaluation Criteria in Solid Tumours. The TACE group had the corresponding rates at 0%, 21.2%, 63.5% and 15.4% respectively (P < 0.0001). The 1‐year, 3‐year and 5‐year survival rates were 84.6%, 49.2% and 32.3% respectively, in the HIFU group and 69.2%, 29.8% and 2.3% respectively, in the TACE group (P = 0.001).
Conclusion
HIFU ablation is a safe and effective method for unresectable HCCs. A survival benefit is observed over sole TACE.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Carcinoma, Hepatocellular - blood supply</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Chemoembolization, Therapeutic - adverse effects</subject><subject>Chemoembolization, Therapeutic - mortality</subject><subject>Disease Progression</subject><subject>Female</subject><subject>HCC</subject><subject>HIFU</subject><subject>High-Intensity Focused Ultrasound Ablation - adverse effects</subject><subject>High-Intensity Focused Ultrasound Ablation - mortality</subject><subject>Hong Kong</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>liver cancer</subject><subject>Liver Neoplasms - blood supply</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>morbidity</subject><subject>mortality</subject><subject>non-invasive treatment</subject><subject>Risk Factors</subject><subject>survival</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Tumor Burden</subject><issn>1478-3223</issn><issn>1478-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcFu1DAURSMEoqWw4AeQl7DI1I6dOFlCgaHSCBZAkdhYL84zY3DiwXYGwj_wz7hMOzuEN7auzj2ydIviMaMrls-5s_sVq4QUd4pTJmRb8oqzu8d3xU-KBzF-pZR1Xc3uFyeVEDWjVXNa_H4_h73dgyMwgVuijcQbsrVftqWdEk7RpoUYr-eIA5ldChD9PA0kbTHAbiH7uCI5nCKEhMFmj97i6HHsvbO_IFk_5Xog8xQwok7QOyRb3EHyGp2bHQSiIWg7-RHiw-KeARfx0c19Vnx8_erDxZty8259efF8U2rRVKJs6SA7SqXWfVPzvpYdoxLrGngOGmybHKEZqMk5M8b0AKYyrdSyGyrecn5WPD14d8F_nzEmNdp4_R-Y0M9RsaZpK9F1jP0frblkrehYm9FnB1QHH2NAo3bBjhAWxai6HkrlodTfoTL75EY79yMOR_J2mQycH4Af1uHyb5PaXF7dKstDw8aEP48NCN9UI7ms1ae3a7UWmxfN1eeXquN_AEBDsFc</recordid><startdate>201407</startdate><enddate>201407</enddate><creator>Cheung, Tan To</creator><creator>Poon, Ronnie T. P.</creator><creator>Jenkins, Caroline R.</creator><creator>Chu, Ferdinand S. K.</creator><creator>Chok, Kenneth S. H.</creator><creator>Chan, Albert C. Y.</creator><creator>Tsang, Simon H. Y.</creator><creator>Dai, Wing Chiu</creator><creator>Yau, Thomas C. C.</creator><creator>Chan, See Ching</creator><creator>Fan, Sheung Tat</creator><creator>Lo, Chung Mau</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>201407</creationdate><title>Survival analysis of high-intensity focused ultrasound therapy vs. transarterial chemoembolization for unresectable hepatocellular carcinomas</title><author>Cheung, Tan To ; Poon, Ronnie T. P. ; Jenkins, Caroline R. ; Chu, Ferdinand S. K. ; Chok, Kenneth S. H. ; Chan, Albert C. Y. ; Tsang, Simon H. Y. ; Dai, Wing Chiu ; Yau, Thomas C. C. ; Chan, See Ching ; Fan, Sheung Tat ; Lo, Chung Mau</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4624-80d79007ccb653b579107e55a3cb66e86b57efd0f9101fffbaaf2f87c79d23833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Carcinoma, Hepatocellular - blood supply</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Chemoembolization, Therapeutic - adverse effects</topic><topic>Chemoembolization, Therapeutic - mortality</topic><topic>Disease Progression</topic><topic>Female</topic><topic>HCC</topic><topic>HIFU</topic><topic>High-Intensity Focused Ultrasound Ablation - adverse effects</topic><topic>High-Intensity Focused Ultrasound Ablation - mortality</topic><topic>Hong Kong</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>liver cancer</topic><topic>Liver Neoplasms - blood supply</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>morbidity</topic><topic>mortality</topic><topic>non-invasive treatment</topic><topic>Risk Factors</topic><topic>survival</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Tumor Burden</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cheung, Tan To</creatorcontrib><creatorcontrib>Poon, Ronnie T. P.</creatorcontrib><creatorcontrib>Jenkins, Caroline R.</creatorcontrib><creatorcontrib>Chu, Ferdinand S. K.</creatorcontrib><creatorcontrib>Chok, Kenneth S. H.</creatorcontrib><creatorcontrib>Chan, Albert C. Y.</creatorcontrib><creatorcontrib>Tsang, Simon H. Y.</creatorcontrib><creatorcontrib>Dai, Wing Chiu</creatorcontrib><creatorcontrib>Yau, Thomas C. C.</creatorcontrib><creatorcontrib>Chan, See Ching</creatorcontrib><creatorcontrib>Fan, Sheung Tat</creatorcontrib><creatorcontrib>Lo, Chung Mau</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cheung, Tan To</au><au>Poon, Ronnie T. P.</au><au>Jenkins, Caroline R.</au><au>Chu, Ferdinand S. K.</au><au>Chok, Kenneth S. H.</au><au>Chan, Albert C. Y.</au><au>Tsang, Simon H. Y.</au><au>Dai, Wing Chiu</au><au>Yau, Thomas C. C.</au><au>Chan, See Ching</au><au>Fan, Sheung Tat</au><au>Lo, Chung Mau</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival analysis of high-intensity focused ultrasound therapy vs. transarterial chemoembolization for unresectable hepatocellular carcinomas</atitle><jtitle>Liver international</jtitle><addtitle>Liver Int</addtitle><date>2014-07</date><risdate>2014</risdate><volume>34</volume><issue>6</issue><spage>e136</spage><epage>e143</epage><pages>e136-e143</pages><issn>1478-3223</issn><eissn>1478-3231</eissn><abstract>Background & Aims
High‐intensity focused ultrasound (HIFU) ablation is a non‐invasive treatment for unresectable hepatocellular carcinomas (HCCs), but long‐term survival analysis is lacking. This study was to analyse its outcome compared to that of transarterial chemoembolization (TACE).
Methods
From October 2003 to September 2010, 113 patients received HIFU ablation as a treatment of HCCs at our hospital. Twenty‐six patients had HCCs sized 3–8 cm. Fifty‐two patients with matched tumour characteristics having TACE as primary treatment were selected for comparison. Short‐term outcome and long‐term survival were analysed.
Results
In the HIFU group (n = 26), 46 tumours were ablated. The median age of the patients was 69 (49–84) years. The median tumour size was 4.2 (3–8) cm. In the TACE group (n = 52), the median age of the patients was 67 (44–84) years. The median tumour size was 4.8 (3–8) cm. There was no hospital mortality in any of the groups. In the HIFU group, the rates of complete tumour response, partial tumour response, stable disease and progressive disease were 50%, 7.7%, 25.6% and 7.7% respectively, according to the modified Response Evaluation Criteria in Solid Tumours. The TACE group had the corresponding rates at 0%, 21.2%, 63.5% and 15.4% respectively (P < 0.0001). The 1‐year, 3‐year and 5‐year survival rates were 84.6%, 49.2% and 32.3% respectively, in the HIFU group and 69.2%, 29.8% and 2.3% respectively, in the TACE group (P = 0.001).
Conclusion
HIFU ablation is a safe and effective method for unresectable HCCs. A survival benefit is observed over sole TACE.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>24451026</pmid><doi>10.1111/liv.12474</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-3223 |
| ispartof | Liver international, 2014-07, Vol.34 (6), p.e136-e143 |
| issn | 1478-3223 1478-3231 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1668249911 |
| source | Access via Wiley Online Library; MEDLINE |
| subjects | Aged Aged, 80 and over Carcinoma, Hepatocellular - blood supply Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - therapy Chemoembolization, Therapeutic - adverse effects Chemoembolization, Therapeutic - mortality Disease Progression Female HCC HIFU High-Intensity Focused Ultrasound Ablation - adverse effects High-Intensity Focused Ultrasound Ablation - mortality Hong Kong Humans Kaplan-Meier Estimate liver cancer Liver Neoplasms - blood supply Liver Neoplasms - mortality Liver Neoplasms - pathology Liver Neoplasms - therapy Male Middle Aged morbidity mortality non-invasive treatment Risk Factors survival Time Factors Treatment Outcome Tumor Burden |
| title | Survival analysis of high-intensity focused ultrasound therapy vs. transarterial chemoembolization for unresectable hepatocellular carcinomas |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-30T22%3A50%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20analysis%20of%20high-intensity%20focused%20ultrasound%20therapy%20vs.%20transarterial%20chemoembolization%20for%20unresectable%20hepatocellular%20carcinomas&rft.jtitle=Liver%20international&rft.au=Cheung,%20Tan%20To&rft.date=2014-07&rft.volume=34&rft.issue=6&rft.spage=e136&rft.epage=e143&rft.pages=e136-e143&rft.issn=1478-3223&rft.eissn=1478-3231&rft_id=info:doi/10.1111/liv.12474&rft_dat=%3Cproquest_cross%3E1537184918%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1537184918&rft_id=info:pmid/24451026&rfr_iscdi=true |